UAVITA-SYSTEMS
On July 29, 2021, UAVita Systems made history with a world aviation industry first – autonomous drone delivery of commercial packages between two major cities.
The Nova poshta commercial flight of UAVita’s DISCOVERY D-80 drone between Kyiv and Kharkiv, two major cities in Ukraine, was 480 km between takeoff and landing and carried a load of five parcels for delivery. The flight was fully autonomous from takeoff to waypoint navigation to landing and crossed several rivers, highways, avoiding populated areas, infrastructure objects and restricted airspace.
Airspace for the flight was reserved with local air traffic control, state air services, and several military authorities. The flight was operated by UAVita’s local Ukraine company, Aerodrone.
"The flight went exactly as planned," said Yuri Pederiy, CTO of UAVita. "Nova poshta was very pleased with the results."
DISCOVERY’s average air speed was 100 kph, with an altitude of 300 meters and total flight time was 4:45 hours a full hour ahead of schedule due to a tail wind.
"Commercial UAV with packages over the distance of 480 km is first in the world," said Oleksandr Bulba, CEO of Nova poshta. "Beside Nova poshta there is no other logistic company that has completed this flight. Our plans are to shorten the flight time to 3 hours to cover the same distance and scale up package drone delivery and make it more affordable to our customers."
Nova poshta’s and UAVita’s next autonomous parcel delivery test flight will take place in late August between the cities of Kyiv and L’viv. The target is to eventually reduce the flight time even further by deploying UAVita’s next generation drones.
“Most conventional drone deliveries are focused on last mile delivery within few kilometers. UAVita took the leap and developed intercity package delivery. This capability adds more flexibility to shipping urgent and high value packages especially to remote locations that are difficult to reach by ground transportation. Combining last mile and intercity delivery can further automate the logistic chain and optimize the operating costs for the courier companies,” explained Pederiy.
Nova poshta is a private Ukrainian postal and courier company and the leader of the logistics in the Ukraine market that provides express delivery of documents, freight and parcels for individuals and businesses. The company delivers shipments through more than 8500 branches, 6700 lockers, and to the customer’s physical address. In 2020 Nova poshta delivered over 318 million shipments throughout Ukraine.
UAVita is a designer, manufacturer and integrator of purpose-built fixed wing high payload autonomous drones. UAVita’s DISCOVERY D-80 drone was recently awarded top place in the Krypto Labs Drone X Challenge 2020 . The DISCOVERY is an industry leading drone with a maximum payload of 80 kg and non-stop flight time of 10 hours or 1000 km. UAVita is set to launch their next generation fixed wing drone that has a maximum payload of 340 kg and non-stop flight time of 30 hours or 4500 km.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805006107/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom